We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ALXO market cap is 96.52M. The company's latest EPS is USD -3.0488 and P/E is -0.60.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -53.28M | -48.02M | -37.76M | -41.53M | -32.57M |
Net Income | -50.99M | -45.47M | -35.58M | -39.4M | -30.71M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 4.8M | 1.18M | 0 | 0 | 0 |
Operating Income | -19.18M | -43.66M | -83.56M | -127.44M | -170.28M |
Net Income | -23.27M | -50.94M | -83.46M | -123.48M | -160.81M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 220.11M | 242.55M | 212.65M | 214.62M | 185.72M |
Total Liabilities | 51.36M | 52.84M | 48.46M | 55.3M | 48.91M |
Total Equity | 168.75M | 189.71M | 164.2M | 159.32M | 136.81M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 10.68M | 436.05M | 380.18M | 306.49M | 242.55M |
Total Liabilities | 10.95M | 6.21M | 17.13M | 43.03M | 52.84M |
Total Equity | -70.64M | 429.85M | 363.05M | 263.46M | 189.71M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -90.69M | -130.36M | -37.92M | -64.49M | -89.87M |
Investing | 61.32M | 44.66M | 26.47M | 27.38M | 53.07M |
Financing | 125k | 59.29M | 3.09M | 30.24M | 30.49M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -14.25M | -38.29M | -68.1M | -89.22M | -130.36M |
Investing | -353k | 610k | -4.92M | -235.42M | 44.66M |
Financing | 15.36M | 462.88M | 2.47M | 9.86M | 59.29M |
Market Cap | 96.52M |
Price to Earnings Ratio | -0.60 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 4.31 |
Price to Book Ratio | 0.51 |
Dividend Yield | - |
Shares Outstanding | 52.74M |
Average Volume (1 week) | 2.34M |
Average Volume (1 Month) | 1.44M |
52 Week Change | -88.15% |
52 Week High | 17.825 |
52 Week Low | 1.19 |
Spread (Intraday) | 0.07 (3.74%) |
Company Name | ALX Oncology Holdings Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.alxoncology.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions